The pursuit of a healthy life has been a trendy and serious issue for decades.
Undoubtedly, emerging antibiotics will be a lighthouse to guide all mankind towards happiness.
Dr.George has involved in biomedical research field for over a decade, specializing in the research and development of new compounds and new drugs. George has achieved some impressive milestones after graduated from the Department of Plant Pathology, National Chung Hsing University:
2018-Successfully transferred the plant protection Streptomyces Padanus PMS-702 composition and preparation and further improved it into the core extraction technology-ExtrOTM.Established Anti-Microbial Savior BioteQ Co., Ltd. (AMS BioteQ).
2021-AMS BioteQ joined the emerging stock market successfully in Dec.
CEO Calvin holds an MBA in Business Administration with a focus on Finance from California State Polytechnic University, Pomona. With expertise in venture capital, he has served as a director of the Securities Over-the-Counter Market and as a board member of the Securities and Futures Investors Protection Center in Taiwan. As the Chairman of Taiwan Venture Capital and Taishin Securities Venture Capital, he has led companies to growth and innovation in a competitive market.
Drug Development| Instrumentation| Quality Control| GLP
Dr. Ian earned his Ph.D from the Institute of Food Science and Technology at National Taiwan University. His expertise includes new drug development, instrumental analysis, quality control, and polysaccharide testing. He holds internationally recognized certifications including ISO/IEC 17025 and GLP. Dr. Chang’s blend of academic rigor and hands-on industry experience strengthens our capabilities in pharmaceutical innovation and food safety. His exceptional leadership in cross-functional integration and quality enhancement directly supports our R&D efficiency, accelerates time-to-market, and technological innovation, therefore contributing significantly to the company's competitive edge.
Ms. Hsu Li-Yu, Director, graduated from National Chung Hsing University. She specializes in internal control, auditing, and IPO guidance, with expertise in accounting and shareholder services. Her leadership drives corporate efficiency, compliance, and growth.
Director Yeh is graduated from the Institute of Biomedical Engineering, National Taiwan University of Science and Technology, specializing in the development and application of drug carriers and wound dressings. Mainly executing 2019 CITD and 2020 SBIR phase I, respectively.
Hong is graduated from the Department of Biomedical Sciences and Engineering, National Central University, specializing in biomaterial and related techniques, major in the development and application of hydrogel dressings.
Biomedical Research| Cell signaling |Animal physiology
Dr. Catherine, a graduate from the Institute of Basic Medical Sciences, National Cheng-Kung University, brings over 20 years of extensive laboratory experience spanning physiology, hepatoma research, neuroscience, metabolism, and cell biology. She specializes in the mechanism of cell signaling transduction, laboratory establishment, project management & execution. At AMS BioteQ she is leading the team of researchers in the development of anti-cancer and anti-viral drugs while actively driving the initiation and advancement of multiple new research projects.
Dr. Chou holds a Ph.D. from National Sun Yat-sen University, he specializes in organic synthesis and chemical biology. At AMS BioteQ, his work focuses on the design of bioactive molecules and the investigation of their biological functions, advancing innovation at the interface of chemistry and biology.
Dr. Harper, a graduate from National Sun Yat-sen University, specializes in quality auditing and product development. Her expertise fosters effective cross-functional collaboration, significantly improving operational efficiency and competitive advantage. At AMS BioteQ, she leads the development and continuous improvement of the company’s Quality Management System (QMS), ensuring rigorous compliance with international standards and driving a culture of operational excellence.
Space Physics| Surfactants Chemistry| Environmental sustainability| Data analysis
Dr. Reyes earned his PhD in Physics from National Cheng Kung University, majoring in theoretical space physics. He specializes in applying statistical data analysis to understand intricate physical and chemical processes, showing remarkable creativity in designing and optimizing surfactants to boost product effectiveness while minimizing environmental impact. At AMS BioteQ, he is responsible for Seep Plug and Sustainable Resources Development, in addition to managing the overall progress of various projects. His role includes overseeing the tracking and evaluation of individual project milestones to ensure timely and efficient execution. He works closely with cross-functional teams to align project objectives with organizational goals, ensuring compliance with sustainability standards and technical requirements.
Drug Development | Oncology Research | Immunotherapy | Nanomedicine | Academic Writer and Communicator
Dr. Richa, a graduate of Kaohsiung Medical University, specializes in the development of nanoparticle-based drug delivery systems and T cell–based immunotherapeutic strategies for cancer treatment. At AMS BioteQ, she applies her expertise in the development of anti-cancer and anti-viral drugs to drive innovation in cancer therapies and treatments for various skin diseases.
Dr. Pandey also oversees global collaborations with CROs for the testing of anti-viral and anti-cancer drugs. Additionally, she actively pursues new ideas to develop innovative medicines derived from natural sources.
Ms. Hsiuyun Chen , Assistant Manager, specializes in marketing planning, brand public relations, and exhibition planning. Leveraging her strong design background and creative thinking, she excels in integrating brand concepts with market demands to craft unique marketing strategies and visual identities. Focused on enhancing brand image and market influence, she creates significant commercial value for enterprises.
